Date: August 05, 2026
Board Meeting Outcomes
- The company confirms no deviation or variation in the use of proceeds from funds raised through its Initial Public Offering (IPO) for the quarter ended June 30, 2026.
- This statement has been duly reviewed by the Audit Committee of the Company.
Financial Results (Fund Utilization)
The company raised total IPO proceeds of ₹126 crore. Detailed utilization against original objects:
Funding for SteriPort manufacturing line at Hariyala, Kheda, Gujarat:
- Original Allocation: ₹7,000.00 lakhs
- Funds Utilized: ₹6,004.87 lakhs
- Deviation/Variation: None
Funding for SVP manufacturing line at Hariyala, Kheda, Gujarat:
- Original Allocation: ₹3,013.11 lakhs
- Funds Utilized: ₹745.88 lakhs
- Deviation/Variation: None
General corporate purposes:
- Original Allocation: ₹660.46 lakhs
- Modified Allocation: ₹302.08 lakhs (modified during quarter ended September 30, 2025)
- Funds Utilized: ₹302.08 lakhs
- Deviation/Variation: None
Issue Expenses:
- Original Allocation: ₹1,926.43 lakhs
- Modified Allocation: ₹2,284.81 lakhs (modified during quarter ended September 30, 2025)
- Funds Utilized: ₹2,284.81 lakhs
- Deviation/Variation: None
Other Operational / Legal / Strategic Disclosures
Historical Modification Note: During the quarter ended September 30, 2025, the issue expenses were modified to account for GST payment made over the cost as per the Offer Document filed for the IPO. This modification was certified by an Independent Chartered Accountant and affirmed by the monitoring agency CRISIL Ratings Limited. Consequently, general corporate purpose expenses were reduced proportionally.
Monitoring Agency: CRISIL Ratings Limited serves as the monitoring agency for the IPO fund utilization.
Audit Committee Review: The Audit Committee reviewed the statement and had no comments.
Auditor's Comments: No auditor comments were provided on this statement.